Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
14 Aug 24
8-K/A
Material Modifications to Rights of Security Holders
16 Jul 24
8-K/A
Other Events
16 Jul 24
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jul 24
8-K
Other Events
16 Jul 24
8-K
Changes in Registrant's Certifying Accountant
21 Jun 24
8-K
Material Modifications to Rights of Security Holders
12 Jun 24
10-Q
2024 Q1
Quarterly report
15 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Other Events
20 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
1 Feb 24
8-K
Other Events
29 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
8-K
Departure of Directors or Certain Officers
28 Dec 23
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
14 Nov 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Jul 23
8-K
Material Modifications to Rights of Security Holders
12 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
10 May 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Entry into a Material Definitive Agreement
4 Apr 23
8-K
Entry into a Material Definitive Agreement
3 Apr 23
8-K
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
30 Mar 23
10-K
2022 FY
Annual report
7 Mar 23
8-K
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
7 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
Latest ownership filings
4
Ferdinand Groenewald
16 Aug 24
4
Melinda Lackey
16 Aug 24
4
Holger Weis
10 Jun 24
4
Jaime Vieser
10 Jun 24
4
Robert W Postma
10 Jun 24
4
Robert Hofmeister
10 Jun 24
SC 13G/A
DISCOVERY CAPITAL MANAGEMENT, LLC / CT
14 Feb 24
SC 13G/A
MSD Partners, L.P.
13 Feb 24
4
Dale Curtis Jr. Hogue
23 Jan 24
4
Dale Curtis Jr. Hogue
3 Jan 24
3
Dale Curtis Jr. Hogue
3 Jan 24
4
Kevin S. Sr. Boyle
5 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
Robert W Postma
8 Jun 23
4
Robert Hofmeister
8 Jun 23
4
Mary Thistle
8 Jun 23
4
James Huang
8 Jun 23
4
Jaime Vieser
8 Jun 23
4
Holger Weis
8 Jun 23
4
Robert Hofmeister
19 Apr 23
3
Robert Hofmeister
19 Apr 23
4
Abhishek K Srivastava
17 Mar 23
4
Michael Wong
17 Mar 23
4
Kevin S. Sr. Boyle
17 Mar 23
4
Drew Deniger
17 Mar 23
4
Melinda Lackey
17 Mar 23
SC 13G/A
MSD Partners, L.P.
14 Feb 23
SC 13G/A
DISCOVERY CAPITAL MANAGEMENT, LLC / CT
14 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
STATE STREET CORP
20 Jan 23
4
Robert W Postma
1 Dec 22
4
Jaime Vieser
1 Dec 22
4
Drew Deniger
19 Sep 22
4
Abhishek K Srivastava
19 Sep 22
4
Michael Wong
19 Sep 22
4
Melinda Lackey
19 Sep 22
4
Kevin S. Sr. Boyle
1 Sep 22
4
Abhishek K Srivastava
16 Aug 22
3
Abhishek K Srivastava
15 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22